The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone
Abstract
Purpose: When designing this trial, there was no evidence that salvage chemotherapy (SLC) in advanced gastric cancer (AGC) resulted in substantial prolongation of survival when compared with best supportive care (BSC). However, SLC is often offered to pretreated patients with AGC for anecdotal reasons. Patients and Methods: Patients with AGC with one or two prior chemotherapy regimens involving both fluoropyrimidines and platinum and with an Eastern Cooperative Oncology Group performance status (PS) 0 or 1 were randomly assigned in a ratio of 2:1 to SLC plus BSC or BSC alone. Choice of SLC—either docetaxel 60 mg/m 2 every 3 weeks or irinotecan 150 mg/m 2 every 2 weeks—was left to the discretion of investigators. Primary end point was overall survival (OS). Results: Median OS was 5.3 months among 133 patients in the SLC arm and 3.8 months among 69 patients in the BSC arm (hazard ratio, 0.657; 95% CI, 0.485 to 0.891; one-sided P = .007). OS benefit for SLC was consistent in most of the prospectively defined subgroups, including age, PS, number of prior treatments, metastatic sites, hemoglobin levels, and response to prior chemotherapy. SLC was generally well tolerated, and adverse events were similar in the SLC and BSC arms. We found no median OS difference between docetaxel and irinotecan (5.2 v 6.5 months; P = .116). Conclusion: To our knowledge, this is the largest phase III trial comparing SLC plus BSC with BSC alone in AGC. In pretreated patients, SLC is tolerated and significantly improves OS when added to BSC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
(2012) · Hepatogastroenterology · doi:10.5754/hge12469 · Cited by 3,178
Wagner, A. D., Grothe, W., Haerting, J., Kleber, G., Grothey, A., & Fleig, W. E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0245 · Cited by 1,171
Thuss-Patience, P. C., Kretzschmar, A., Bichev, D., Deist, T., Hinke, A., Breithaupt, K., Dogan, Y., Gebauer, B., Schumacher, G., & Reichardt, P. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.002 · Cited by 612
Sample Sizes Based on the Log-Rank Statistic in Complex Clinical Trials
Lakatos, E. (1988) · Biometrics · doi:10.2307/2531910 · Cited by 350
S3-Leitlinie „Magenkarzinom” -
Moehler, M., Al-Batran, S.-E., Andus, T., Anthuber, M., Arends, J., Arnold, D., Aust, D., Baier, P., Baretton, G., Bernhardt, J., et al. (2011) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0031-1273201 · Cited by 283
Nationwide Cancer Incidence in Korea, 2003-2005
Won, Y., Sung, J., Jung, K., Kong, H., Park, S., Shin, H., Park, E., Ahn, Y., Hwang, I. K., Lee, D., et al. (2009) · Cancer Research and Treatment · doi:10.4143/crt.2009.41.3.122 · Cited by 137
Self-citationCPT-11 in gastrointestinal cancer
Bleiberg, H. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00423-7 · Cited by 102
Review of second-line chemotherapy for advanced gastric adenocarcinoma
Wilson, D., Hiller, L., & Geh, J. I. (2004) · Clinical Oncology · doi:10.1016/j.clon.2004.10.006 · Cited by 63
Cherny, N. I., Abernethy, A. P., Strasser, F., Sapir, R., Currow, D. C., & Zafar, S. Y. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.21.9592 · Cited by 54
The role of chemotherapy in the current treatment of gastric cancer
Cutsem, E. V., Haller, D. G., & Ohtsu, A. (2002) · Gastric Cancer · doi:10.1007/s10120-002-0219-y · Cited by 36
Quality of life in patients with advanced gastric cancer treated with second-line chemotherapy
Park, S. H., Lee, W. K., Chung, M., Bang, S., Cho, E. K., Lee, J. H., & Shin, D. B. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0055-y · Cited by 34
Self-citationLim, D. H., Park, S. H., Park, K. W., Kang, J. H., Oh, S. Y., Hwang, I. G., Kwon, J. M., Lee, S., Lee, H.-Y., Kim, H. S., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-583 · Cited by 14
Self-citation
Cited by
Smyth, E. C., Nilsson, M., Grabsch, H. I., van Grieken, N. C., & Lordick, F. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31288-5 · Cited by 4,803
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438
Self-citationJapanese gastric cancer treatment guidelines 2014 (ver. 4)
Japanese Gastric Cancer Association (2017) · Gastric Cancer · doi:10.1007/s10120-016-0622-4 · Cited by 2,429
Kang, Y.-K., Boku, N., Satoh, T., Ryu, M.-H., Chao, Y., Kato, K., Chung, H. C., Chen, J.-S., Muro, K., Kang, W. K., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31827-5 · Cited by 2,252
Self-citationFuchs, C. S., Tomasek, J., Yong, C. J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. V., Aprile, G., Ferry, D. R., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,188
Metadata
- Authors
- Kang, J. H., Lee, S. I., Lim, D. H., Park, K.-W., Oh, S. Y., Kwon, H.-C., Hwang, I. G., Lee, S.-C., Nam, E., Shin, D. B., Lee, J., Park, J. O., Park, Y. S., Lim, H. Y., Kang, W. K., & Park, S. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-05-01
- Volume
- 30
- Issue
- 13
- Pages
- 1513-1518
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2114734455
- Cited by
- 660
- References
- 13
- FWCI
- 48.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.